Breaking News Instant updates and real-time market news.

FOMX

Foamix

$2.92

-0.34 (-10.43%)

08:12
10/23/19
10/23
08:12
10/23/19
08:12

Foamix enters manufacturing, supply agreement for AMZEEQ, FMX103

Foamix Pharmaceuticals announced that it has entered into a long term contract manufacturing and supply agreement with ASM Aerosol-Service for the Company's recently approved AMZEEQ topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older and for its product candidate FMX103 topical foam, 1.5% for the potential treatment of moderate to severe papulopustular rosacea in adults. Under the terms of the agreement, ASM will manufacture and supply AMZEEQ and FMX103 at its facility in Mohlin, Switzerland. With the receipt of FDA approval of AMZEEQ and entry into the contract manufacturing and supply agreement with ASM, the Company now has access to up to an additional $20M of financing under its existing credit agreement with Perceptive and OrbiMed to fund the commercial launches of AMZEEQ and, pending FDA approval, FMX103.

FOMX Foamix
$2.92

-0.34 (-10.43%)

10/21/19
HCWC
10/21/19
NO CHANGE
Target $11
HCWC
Buy
Foamix price target raised to $11 from $10 at H.C. Wainwright
Foamix Pharmaceuticals last week arguably the most successful week in its history as a public company, with FMX101 being approved by the FDA for treatment of moderate-to-severe acne vulgaris and FMX103 being accepted for review by the agency as a treatment for moderate-to-severe papulopustular rosacea, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on the shares and boosted his price target to $11 from $10.
10/16/19
LEHM
10/16/19
NO CHANGE
Target $10
LEHM
Overweight
Barclays likes Foamix setup into October 20 FDA action date
Barclays analyst Balaji Prasad highlights Foamix Pharmaceuticals' key upcoming FDA action date of October 20 for FMX-101 in acne. The analyst says ~75% of his $10 price target is derived from FMX-101, and that approval could add another $2, or 320% potential upside from current share levels. The analyst sees a 90% probability of success and forecasts 2025 risk adjusted sales of $202M. Prasad continues to like Foamix's risk/reward setup going into the October 20 PDUFA and he reiterates an Overweight rating on the shares.
10/08/19
CANT
10/08/19
NO CHANGE
Target $15
CANT
Overweight
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
Cantor Fitzgerald analyst Louise Chen says her 25 physician survey supports her positive view on the market opportunity for Foamix's FMX10. If approved, FMX101 has the potential to address a significant unmet need in the treatment of moderate-to-severe acne, which remains a difficult condition, Chen tells investors in a research note. She reiterates an Overweight rating on Foamix shares with a $15 price target ahead of the upcoming FDA action date for FMX101 on October 20. The analyst thinks the Street is underestimating the uptake of acne drugs.
06/11/19
LEHM
06/11/19
INITIATION
Target $10
LEHM
Overweight
Foamix initiated with an Overweight at Barclays
Barclays analyst Balaji Prasad started Foamix Pharmaceuticals with an Overweight rating and $10 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.

TODAY'S FREE FLY STORIES

ALB

Albemarle

$67.72

-0.29 (-0.43%)

05:37
11/12/19
11/12
05:37
11/12/19
05:37
Downgrade
Albemarle rating change  »

Albemarle downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.86

0.11 (0.62%)

05:36
11/12/19
11/12
05:36
11/12/19
05:36
Downgrade
Cellular Biomedicine rating change  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNIRF

Senior plc

$0.00

(0.00%)

05:36
11/12/19
11/12
05:36
11/12/19
05:36
Downgrade
Senior plc rating change  »

Senior plc downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOLVY

Solvay

$0.00

(0.00%)

05:34
11/12/19
11/12
05:34
11/12/19
05:34
Upgrade
Solvay rating change  »

Solvay upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

BOX

Box

$16.45

-0.495 (-2.92%)

05:32
11/12/19
11/12
05:32
11/12/19
05:32
Downgrade
Box rating change  »

Box downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

CTVA

Corteva

$26.74

0.54 (2.06%)

05:30
11/12/19
11/12
05:30
11/12/19
05:30
Initiation
Corteva initiated  »

Corteva initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

IFJPY

Informa

$0.00

(0.00%)

05:30
11/12/19
11/12
05:30
11/12/19
05:30
Upgrade
Informa rating change  »

Informa upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPKFF

LPKF Laser & Electronics

$0.00

(0.00%)

05:29
11/12/19
11/12
05:29
11/12/19
05:29
Downgrade
LPKF Laser & Electronics rating change  »

LPKF Laser &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETN

Eaton

$91.87

-0.35 (-0.38%)

05:28
11/12/19
11/12
05:28
11/12/19
05:28
Downgrade
Eaton rating change  »

Eaton downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 19

    Nov

  • 19

    Nov

COVTY

Covestro

$0.00

(0.00%)

05:27
11/12/19
11/12
05:27
11/12/19
05:27
Downgrade
Covestro rating change  »

Covestro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPRUY

Kering

$0.00

(0.00%)

05:27
11/12/19
11/12
05:27
11/12/19
05:27
Upgrade
Kering rating change  »

Kering upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$16.11

-0.1 (-0.62%)

05:26
11/12/19
11/12
05:26
11/12/19
05:26
Upgrade
Fiat Chrysler rating change  »

Fiat Chrysler upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUGOY

Peugeot

$0.00

(0.00%)

05:26
11/12/19
11/12
05:26
11/12/19
05:26
Upgrade
Peugeot rating change  »

Peugeot upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAVS

Ageagle Aerial Systems

$0.42

0.0385 (10.13%)

05:25
11/12/19
11/12
05:25
11/12/19
05:25
Conference/Events
Ageagle Aerial Systems to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

NNGRY

NN Group

$0.00

(0.00%)

05:25
11/12/19
11/12
05:25
11/12/19
05:25
Downgrade
NN Group rating change  »

NN Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$17.10

-0.22 (-1.27%)

05:23
11/12/19
11/12
05:23
11/12/19
05:23
Earnings
Embraer backs FY20 revenue view of $2.5B-$2.8B »

May not compare to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PRBZF

Premium Brands

$0.00

(0.00%)

05:22
11/12/19
11/12
05:22
11/12/19
05:22
Downgrade
Premium Brands rating change  »

Premium Brands downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$17.10

-0.22 (-1.27%)

05:21
11/12/19
11/12
05:21
11/12/19
05:21
Earnings
Embraer backs FY19 revenue guidance of $5.3M-$5.7M, consensus $5.37M »

Embraer reaffirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

OZMLF

Oz Minerals

$0.00

(0.00%)

05:21
11/12/19
11/12
05:21
11/12/19
05:21
Downgrade
Oz Minerals rating change  »

Oz Minerals downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SESN

Sesen Bio

$1.14

(0.00%)

05:20
11/12/19
11/12
05:20
11/12/19
05:20
Conference/Events
Sesen Bio to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ERJ

Embraer

$17.10

-0.22 (-1.27%)

05:19
11/12/19
11/12
05:19
11/12/19
05:19
Earnings
Embraer reports Q3 EPS (26c), consensus (9c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

AAXN

Axon

$64.41

-0.95 (-1.45%)

05:18
11/12/19
11/12
05:18
11/12/19
05:18
Recommendations
Axon analyst commentary  »

Axon price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

INFO

IHS Markit

$68.90

-0.72 (-1.03%)

05:18
11/12/19
11/12
05:18
11/12/19
05:18
Conference/Events
IHS Markit to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PLNT

Planet Fitness

$67.73

-0.7 (-1.02%)

05:16
11/12/19
11/12
05:16
11/12/19
05:16
Recommendations
Planet Fitness analyst commentary  »

Planet Fitness price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

05:15
11/12/19
11/12
05:15
11/12/19
05:15
General news
Breaking General news story  »

Federal Reserve Board of…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.